This is a similar but slightly different question than the one answered by Attard et al., PMID 34953525. This meta-analysis of randomized trials demonstrated a survival benefit with the addition of 2 years of Abiraterone + ADT compared to ADT in men who received definitive management for N1 prostate...

Multiple randomized phase III clinical trials have tested the use of an NHT plus ADT with ADT alone in patients with mHSPCa. STAMPEDE addressed the question in a variety of patient types including nodal relapse after local therapy. In that trial, abiraterone and corticosteroid were continued until r...